DrugPatentWatch Database Preview
Methylprednisolone sodium succinate - Generic Drug Details
» See Plans and Pricing
What are the generic sources for methylprednisolone sodium succinate and what is the scope of freedom to operate?
Methylprednisolone sodium succinate
is the generic ingredient in four branded drugs marketed by Abbott, Hospira, Hospira Inc, Elkins Sinn, Organon Usa Inc, Abraxis Pharm, Amneal, Aurobindo Pharma Ltd, Bedford Labs, Fresenius Kabi Usa, Hikma, Intl Medication, Sagent Pharms Inc, Teva Parenteral, Watson Labs, and Pharmacia And Upjohn, and is included in forty-seven NDAs. Additional information is available in the individual branded drug profile pages.There are forty drug master file entries for methylprednisolone sodium succinate. Twelve suppliers are listed for this compound.
Summary for methylprednisolone sodium succinate
US Patents: | 0 |
Tradenames: | 4 |
Applicants: | 16 |
NDAs: | 47 |
Drug Master File Entries: | 40 |
Suppliers / Packagers: | 12 |
Bulk Api Vendors: | 82 |
Clinical Trials: | 20 |
Patent Applications: | 6,690 |
Formulation / Manufacturing: | see details |
DailyMed Link: | methylprednisolone sodium succinate at DailyMed |
Recent Clinical Trials for methylprednisolone sodium succinate
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Tel-Aviv Sourasky Medical Center | N/A |
Hospital Sao Domingos | Phase 2 |
Fundação de Medicina Tropical Dr. Heitor Vieira Dourado | Phase 2 |
Pharmacology for methylprednisolone sodium succinate
Drug Class | Corticosteroid |
Mechanism of Action | Corticosteroid Hormone Receptor Agonists |
US Patents and Regulatory Information for methylprednisolone sodium succinate
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hospira | A-METHAPRED | methylprednisolone sodium succinate | INJECTABLE;INJECTION | 085854-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | Start Trial | Start Trial | Start Trial | ||||
Hospira | A-METHAPRED | methylprednisolone sodium succinate | INJECTABLE;INJECTION | 085853-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | Start Trial | Start Trial | Start Trial | ||||
Abraxis Pharm | METHYLPREDNISOLONE SODIUM SUCCINATE | methylprednisolone sodium succinate | INJECTABLE;INJECTION | 089143-001 | Mar 28, 1986 | DISCN | No | No | Start Trial | Start Trial | Start Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:






Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.